Young's modulus and hardness of human trabecular bone with bisphosphonate treatment durations up to 20 years
- PMID: 30488274
- DOI: 10.1007/s00198-018-4760-x
Young's modulus and hardness of human trabecular bone with bisphosphonate treatment durations up to 20 years
Abstract
Bone modulus from patients with osteoporosis treated with bisphosphonates for 1 to 20 years was analyzed. Modulus increases during the first 6 years of treatment and remains unchanged thereafter.
Introduction: Bisphosphonates are widely used for treating osteoporosis, but the relationship between treatment duration and bone quality is unclear. Since material properties partially determine bone quality, the present study quantified the relationship between human bone modulus and hardness with bisphosphonate treatment duration.
Methods: Iliac crest bone samples from a consecutive case series of 86 osteoporotic Caucasian women continuously treated with oral bisphosphonates for 1.1-20 years were histologically evaluated to assess bone turnover and then tested using nanoindentation. Young's modulus and hardness were measured and related to bisphosphonate treatment duration by statistical modeling.
Results: All bone samples had low bone turnover. Statistical models showed that with increasing bisphosphonate treatment duration, modulus and hardness increased, peaked, and plateaued. These models used quadratic terms to model modulus increases from 1 to 6 years of bisphosphonate treatment and linear terms to model modulus plateaus from 6 to 20 years of treatment. The treatment duration at which the quadratic-linear transition (join point) occurred also depended upon trabecular location. Hardness increased and peaked at 12.4 years of treatment; it remained constant for the next 7.6 years of treatment and was insensitive to trabecular location.
Conclusions: Bone modulus increases with bisphosphonate treatment durations up to 6 years, no additional modulus increases occurred after 6 years of treatment. Although hardness increased, peaked at 12.4 years and remained constant for the next 7.6 years of BP treatment, the clinical relevance of hardness remains unclear.
Keywords: Bone biomechanics; Bone hardness; Bone modulus; Bone quality; Nanoindentation.
Similar articles
-
Trabecular bone microcrack accumulation in patients treated with bisphosphonates for durations up to 16 years.J Orthop Res. 2023 May;41(5):1033-1039. doi: 10.1002/jor.25441. Epub 2022 Sep 26. J Orthop Res. 2023. PMID: 36163612 Free PMC article.
-
Stiffness and strength of bone in osteoporotic patients treated with varying durations of oral bisphosphonates.Osteoporos Int. 2016 Sep;27(9):2681-2688. doi: 10.1007/s00198-016-3661-0. Epub 2016 Jul 22. Osteoporos Int. 2016. PMID: 27448808
-
Femoral head trabecular micro-architecture in patients with osteoporotic hip fractures: Impact of bisphosphonate treatment.Bone. 2017 Dec;105:148-153. doi: 10.1016/j.bone.2017.08.020. Epub 2017 Aug 24. Bone. 2017. PMID: 28842364
-
How long should women with postmenopausal osteoporosis be treated with a bisphosphonate?Horm Metab Res. 2013 Sep;45(9):621-8. doi: 10.1055/s-0033-1345207. Epub 2013 Jun 11. Horm Metab Res. 2013. PMID: 23757119 Review.
-
Young's modulus of trabecular bone at the tissue level: A review.Acta Biomater. 2018 Sep 15;78:1-12. doi: 10.1016/j.actbio.2018.08.001. Epub 2018 Aug 4. Acta Biomater. 2018. PMID: 30081232 Review.
Cited by
-
Update on Menopausal Hormone Therapy for Fracture Prevention.Curr Osteoporos Rep. 2019 Dec;17(6):465-473. doi: 10.1007/s11914-019-00549-3. Curr Osteoporos Rep. 2019. PMID: 31741221 Free PMC article. Review.
-
Adynamic bone disorder in chronic kidney disease: meta-analysis and narrative review of potential biomarkers as diagnosis and therapeutic targets.Ren Fail. 2025 Dec;47(1):2530162. doi: 10.1080/0886022X.2025.2530162. Epub 2025 Jul 16. Ren Fail. 2025. PMID: 40669844 Free PMC article. Review.
-
Trabecular bone microcrack accumulation in patients treated with bisphosphonates for durations up to 16 years.J Orthop Res. 2023 May;41(5):1033-1039. doi: 10.1002/jor.25441. Epub 2022 Sep 26. J Orthop Res. 2023. PMID: 36163612 Free PMC article.
-
Alendronate for Effective Treatment of Male Osteoporosis: An Insight.Curr Pharm Des. 2025;31(1):26-36. doi: 10.2174/0113816128310838240820065324. Curr Pharm Des. 2025. PMID: 39238374 Review.
-
Effect of bisphosphonate on bone microstructure, mechanical strength in osteoporotic rats by ovariectomy.BMC Musculoskelet Disord. 2024 Sep 10;25(1):725. doi: 10.1186/s12891-024-07846-8. BMC Musculoskelet Disord. 2024. PMID: 39256676 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources